bioAffinity Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 75
- Market Cap
- $21.7M
- Introduction
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay
- Conditions
- Lung Cancer
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- bioAffinity Technologies Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05870592
- Locations
- 🇺🇸
Brooke Army Medical Hospital, San Antonio, Texas, United States
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- bioAffinity Technologies Inc.
- Target Recruit Count
- 197
- Registration Number
- NCT03837600
- Locations
- 🇺🇸
Waterbury Pulmonary Associates LLC, Waterbury, Connecticut, United States
🇺🇸Meridian Health, Neptune, New Jersey, United States
🇺🇸Atlantic Respiratory Institute, Summit, New Jersey, United States
Collection of Sputum and Labeling for Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- bioAffinity Technologies Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT03457415
- Locations
- 🇺🇸
Atlantic Respiratory Institute, Summit, New Jersey, United States
🇺🇸Radiology Associates of Albuquerque, Albuquerque, New Mexico, United States
🇺🇸South Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas, United States
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- bioAffinity Technologies Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02388074
- Locations
- 🇺🇸
Radiology Associates of Albuquerque (RAA), Albuquerque, New Mexico, United States
News
bioAffinity Technologies Secures International Patents for CyPath Lung Cancer Diagnostic in China and Canada
bioAffinity Technologies received patent approvals in China and Canada for its CyPath Lung diagnostic platform, which uses flow cytometry analysis of sputum to detect lung cancer.
BioAffinity Technologies Secures Patent for Dual-Target Cancer Therapy Using siRNA Against CD320 and LRP2 Receptors
BioAffinity Technologies received a U.S. patent for a novel cancer therapy that uses small interfering RNAs to simultaneously target CD320 and LRP2 receptors on cancer cell membranes.
bioAffinity Technologies Secures $3.25 Million in Funding to Advance Early Cancer Detection Technology
bioAffinity Technologies has successfully closed a $3.25 million offering, issuing over 10 million shares of common stock along with warrants to purchase additional shares at $0.32 per unit.
CyPath® Lung Demonstrates Clinical Impact in Real-World Lung Cancer Detection Cases
bioAffinity Technologies released clinical evidence showing CyPath® Lung's effectiveness in diagnosing early-stage lung cancer through real-world case studies authored by Dr. Gordon Downie.